Member Info for Muck165

Just some more..

https://www.menoguide.co.uk/

Worth looking at the posts here https://www.linkedin.com/company/agile-life-sciences/posts/?feedView=all

Also worth noting that of the 6 Agile employees on LinkedIn, 4 came after long periods with Arcis Bio, and two others were recruited just a couple of months ago. In short, Whitehurst and Harding nicked key staff from Arcis to develop the offering and are now a recruiting to drive it. Again,only relevant to us if we’re expected to feature in an RTO.

Details on the Agile menopause initiatives, published 11/8.

https://www.ukri.org/news/transforming-the-way-menopause-is-diagnosed-monitored-and-managed/

It’s a service I think is needed. Also interesting to note the company was set up by Whitehurst (previously CEO at Arcis Bio for years) and Jan Harding (previously CSO at Arcis for years). Quite a career risk for the two of them unless they’re properly backed (Hughes) and believe in the offering.

All irrelevant to us of course unless some kind of RTO involving Agile and LSAI is on the cards.

Just an update here…

Randall Whitmore, appointed Director of Digital Health in January, left Vatic this month.

Dan Birch, appointed Marketing Manager in Oct 21, left Vatic in July 2022.

Jake Sylvester, appointed Sales Lead in Oct 21, left Vatic last month and remains “open to work”.

Nobody appears to have been appointed to replace them. I know some don’t like these kinds of posts, but the deathly silence from Vatic (previously prolific on social media), combined with the falling headcount , FDA approval silence and the fact ABDX still await key re-agents from Vatic to begin production, doesn’t feel too encouraging to me.

For anyone interested, but mostly for Hurst

https://hub.pointbiopharma.com/controlarm

Is it just £1.5m though?

We know that £1.5m of the settlement is sitting in a bank account, charged to the DHSC, and that that security crystallises in the “event of default”. “Event of Default” is defined in the security docs as “the technology and construction court makes an final order in the JR proceedings that the company (ie us) repay all or any of the sums paid to the company by the charger (ie DHSC) in respect of all or any of the contracts”.

To me that leaves open the possibility that the court could rule in favour of GLP and COULD order us to repay the DHSC EVERYTHING we got from them under the contracts. In those circumstances the £1.5m would be easily sorted, but what about the balance? Would (or even could) the DHSC decide to waive it?

TBH, I’m not overly concerned because I just can’t see why the DHSC would settle and leave themselves open to this potential scenario, but that doesn’t alter the fact that the potential exists I think.

Let’s face it, it’s a terrible update. The EU customer won’t (in my view) materialise and both of the other covid opps are stuck with regulators. Taiwan has added nothing to its EUA list since May, and Vatic are losing staff and been deathly silent. In that last respect, I did note page 4 of the last FDA virtual town hall;

Q: I was curious if the FDA has any recommendations or advice for saliva-based antigen home tests?

A: So we've seen quite a bit of attempts at saliva-based antigen tests. I don't know exactly why it's been such a challenge. You know, there are a lot of advantages if it would work, but it may be that there's a concentration that's needed, such as with a molecular test.
So some of the molecular tests have not worked quite well in saliva, but that may be due to the concentration effect in extraction. So if you want to attempt it, you would just follow the recommendations, if you want, for antigen test validation. The comparator for saliva would be a nasopharyngeal swab using a high sensitivity molecular central lab test.
I would double check with the FDA before using a comparator test to make sure that it's high sensitivity enough. And then thirty positives and thirty negatives if you're going for symptomatic individuals.
We have recommended to others that want to pursue saliva. If this is a new test, we would recommend that you also consider as a backup and anterior nares swab. So that if you should have any issues with saliva, at least you have anterior nares.

https://www.fda.gov/media/160670/download

Agree, but Taiwan don’t seem to be in any rush - nothing whatsoever has been added to this list since May

https://covid19.mohw.gov.tw/en/cp-5281-63752-206.html

It seems the Tech and Construction court are now taking a summer breather. From what I can see, the High Court won’t be conducting hearings or appeals until October. I don’t know if this applies equally to delivery of judgments - anyone else know on that score?

Yep - an extension of time to oppose request has been granted to these guys, with a “k(now)” test

https://www.biologyworks.com/

Nice to see Rishi looking to expand home testing…looks like he’s getting the message about people taking more responsibility over their own healthcare.

https://news.sky.com/story/rishi-sunak-promises-to-tackle-nhs-backlog-as-liz-truss-pledges-eu-red-tape-bonfire-12656972

Yep - interesting to see the FDA talking about Monkeypox in their regular town hall, usually reserved exclusively for covid testing. See P2 of;

https://www.fda.gov/media/159787/download

I guess it’s ongoing in the sense that no ruling has been given, even though the proceedings themselves have finished. I’m unaware of anything saying we will get a ruling by end of July, but I do think the time must be coming to get one. I check the listings for the following days court business every afternoon, to try and get some advance notice.

TBH I’m a bit confused. ABDX had to lodge £1.5 of the DHSC settlement into a bank account charged to the DHSC. The security docs relating to that charge say the monies will need to be repaid to DHSC in the event of default, which will only be the case (as defined in those docs) if the court orders ABDX to repay monies to ABDX under the ABC19 contracts.

The bit I don’t get is this - if there is a possibility of such an order, why didn’t DHSC require that all settlement monies be held under charge, rather than just £1.5m, and why have ABDX been able to use some of it to pay ODX etc?

Anyway, with glass half full I’m certainly hoping the ruling favours us and we get to keep the £1.5, and in that vein am buoyed by the fact that GLP seem to have given up pressing other covid related JR cases because of the courts attitude to them.

We’re marketing the Wondfo nCov Antigen Test (lateral flow method) through our new e-commerce site. For info, that test received WHO Emergency Use Listing on 18/7 22. Not sure how relevant that is, if at all, given I don’t think we make it, but it is noticeable that the test is 1 of just 9 tests to have received that approval since 2020.

https://extranet.who.int/pqweb/sites/default/files/documents/220718_EUL_SARS-CoV-2_product_list_0.pdf

https://extranet.who.int/pqweb/vitro-diagnostics/coronavirus-disease-covid-19-pandemic-%E2%80%94-emergency-use-listing-procedure-eul-open

Is it just me, or does our new site seem similar to the Vatic site in terms of simplicity and layout….

Noticed that every test is branded Abingdon Simply, except the covid test. I’m assuming, therefore that the test Arise are waiting for pending Taiwanese approval is not the Wondfo test.

“Come in handy” - love it…

Article in the Taipei Times from 15/7 detailing the current covid situation in Taiwan. Interesting that they’re using a saliva test at airports…

https://www.taipeitimes.com/News/front/archives/2022/07/15/2003781786

I’m assuming everyone is still currently employed. I keep an eye on www.Glassdoor.co.U.K., where employees can post reviews about the companies they work for, because often a spate of negative reviews can be the first indication of something wrong/ mass redundancies. So far there has been nothing…

Thanks HDTU - up 29% week on week, and pressure on the NHS rising. We just need to be making an approved test with significant orders.